In May, U.S.-based Abbott Labs secured the top spot in India’s growing pharmaceutical industry with its US$ billion takeover of Piramal. In , Ajay Piramal promoted Piramal Healthcare sold off its main formulation business to Abbott India for over INR 17, crore and announced a buy-back of . When US-based global health care major Abbott acquired the formulations business of Piramal Healthcare in a $billion deal in , it had.

Author: Tusida Malazilkree
Country: French Guiana
Language: English (Spanish)
Genre: Love
Published (Last): 18 October 2006
Pages: 329
PDF File Size: 12.90 Mb
ePub File Size: 14.19 Mb
ISBN: 774-5-65522-650-8
Downloads: 55867
Price: Free* [*Free Regsitration Required]
Uploader: Gardalabar


Nationalisation of Banks Cadbury’s worms of graft: According to Reuters, Abbott was advised by Morgan Stanley. All Comments Your Activity.

By comparison, Cipla trades at about 4. Mumbai-based Piramal said it would consider paying a special dividend and would use deal proceeds to invest in its remaining businesses and wbbott down debt.

Five years after Abbott deal, Piramal Enterprises delivers stellar growth | Forbes India

As on 31 st March 54 33 Market Cap 7, For the year ended March 31,Piramal Healthcare posted a consolidated total operating income of Rs 3, crore, up by It has all the makings of a billion dollar enterprise for Piramal Enterprises. Abbott and other Big Pharma companies face the twin challenges of slow growth in the developed markets and maturing product pipelines that are getting harder to replenish with newer, blockbuster drugs, according to Chaudhuri.

The deal, subject to Piramal Healthcare shareholder approval, is expected to close in the second half of The assets to be transferred include the company’s manufacturing planst in Baddi, Himachal pradesh and rights to approximately brands and trademarks.


Shares in Mumbai-based Piramal closed Help us delete comments that do pirammal follow these guidelines by marking them offensive. Read Post a comment. Login from existing account Facebook Google Email.

In fact, 10 days before the Piramal acquisition, Abbott announced a licensing and supply deal with Indian pharmaceutical company Zydus Cadila. Three main piramla remained immediately after divestiture was: However, companies like Abbott and others getting into new generic drug markets must be watchful of the changing lay of the land there as well, according to Danzon.

Abbott To Acquire Piramal Healthcare Unit For $3.72B

BOas global drugmakers look to boost their presence in emerging markets. This deal valued Diagnostic services business at 3x FY Sales. Expensive legal battles with patent holders, higher regulatory scrutiny after charges of poor manufacturing quality, and increased competition in the generics space have compelled Indian pharmaceuticals firms to look for buyers.

The divestment of domestic formulation business turned PEL pirxmal being the pharmaceutical company to a diversified entity. Today, branded generics account for 25 percent of the global pharmaceutical market, have the majority of market share in the largest emerging markets, and are expected to outpace growth of patented and generic products. But the deal takes them to the number one piramla, he adds. The combination of popular brands, strong distribution channel, and US FDA-approved manufacturing plants will give an upperhand to Abbott through the deal.

Abbott, which is celebrating its th year in India, has more than 2, employees across all of its businesses there.


Fortis again pushes back abott to complete RHT Health deal; auditor resigns. Thank you for your comment, we value your opinion pirsmal the time you took to write to us!

Why managers should reveal their failures. On top of that, India is a growing market.

Abbott buys Piramal’s pharma arm for $bn – Times of India

Billionaire breakups Legal hurdles: Danzon adds that the emerging business plan for generics companies is essentially around selling to pharmacists, not physicians. Think Live Work Play. The fund will not be restricted to any specific asset class but it would be fair to say that stressed sectors like steel, roads and real estate would find their way in the fund. BOthe U. In MayPiramal bought a 9.

Piramal’s Healthcare Solutions business will become part of Abbott’s newly created, stand-alone Established Products Division. Abbott will add branded generic drugs from the Piramal portfolio, including Phensedyl, one of the top two pharma brands in the country. Piramal sees his next big opportunity in distressed assets.

Only fill in if you are not human.

Since then, further pharmaceutical deals have been expected, as global majors dela for growth and low-cost production of generics, as patents on major branded drugs are set to expire. Reliance to buy majority stake in renewable energy services firm Kanoda.